Product

Company

Clareo Health | Study of BHV-1400 in IgA Nephropathy

NCT07054684·15 sites·ClinicalTrials.gov

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Biohaven Therapeutics Ltd.

Age

18–65

Sex

ALL

Healthy volunteers

Not accepted

1. Any secondary IgAN
2. Any cause of chronic kidney disease not diagnosed as IgAN or due to non-IgAN cause

The record

StatusRecruiting

PhasePhase 1

Taking part20

StartedJul 2025

UpdatedJun 23, 2026

Conditions

Where15